BLISTEX BRACKEN LIMITED PARTNERSHIP – Trademark Portfolio
Entity Type: 13
BLISTEX BRACKEN LIMITED PARTNERSHIP holds 8 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 8 filings in this category. The portfolio also extends into Class 3 (Cosmetics & Cleaning) across 2 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include BLISTEX. The owner is based in SEATTLE, WA.
1325 - 4th Avenue, Suite 1402
SEATTLE, WA 98101
Showing of trademarks Trademarks
Trademark Classifications
BLISTEX BRACKEN LIMITED PARTNERSHIP's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Frequently Asked Questions
How many trademarks does BLISTEX BRACKEN LIMITED PARTNERSHIP have?
BLISTEX BRACKEN LIMITED PARTNERSHIP has 8 U.S. trademarks filed with the USPTO. Of these, 3 registered, 5 cancelled.
What trademark classes does BLISTEX BRACKEN LIMITED PARTNERSHIP file in?
BLISTEX BRACKEN LIMITED PARTNERSHIP files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 3 (Cosmetics & Cleaning). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are BLISTEX BRACKEN LIMITED PARTNERSHIP's most well-known trademarks?
BLISTEX BRACKEN LIMITED PARTNERSHIP's registered trademark portfolio includes well-known marks such as BLISTEX. These are among 3 currently registered trademarks in the portfolio.
What is BLISTEX BRACKEN LIMITED PARTNERSHIP's trademark registration success rate?
BLISTEX BRACKEN LIMITED PARTNERSHIP has a 38% trademark registration rate, with 3 out of 8 resolved applications resulting in successful registration. Currently, 0 applications are pending review.